Premium
A Piroxicam Derivative Partly Effective in Chronic Paroxysmal Hemicrania and Hemicrania Continua
Author(s) -
Sjaastad Ottar,
Antonaci Fabio
Publication year - 1995
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1995.hed3509549.x
Subject(s) - piroxicam , medicine , placebo , dermatology , anesthesia , pathology , alternative medicine
Piroxicam beta‐cyclodextrin has recently been observed to be equal to, or even possibly to be superior to, indomethacin (mainly with regard to side effects) in a single case of hemicrania continua. Piroxicam beta‐cyclodextrin, 20 to 40 mg per day, was, accordingly, tried in six patients with chronic paroxysmal hemicrania and six patients with hemicrania continua with a previously proven response to indomethacin. The study was conducted over a period of 3 weeks and in an open fashion. A placebo effect is considered to be negligible in these disorders. In such a comparison, piroxicam beta‐cyclodextrin seemed inferior to indomethacin, in particular in chronic paroxysmal hemicrania.